<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">EUROPEAN SYNCHROTRON RADIATION FACILITY</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Julie</forename><surname>Villanova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Brecht</forename><surname>Laforce</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">X-ray Microspectroscopy and Imaging Group (XMI)</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<addrLine>Krijgslaan 281 S12</addrLine>
									<postCode>B-9000</postCode>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Charlotte</forename><surname>Carlier</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Laboratory of Experimental Surgery</orgName>
								<orgName type="institution">Ghent University Hospital</orgName>
								<address>
									<postCode>B-9000</postCode>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bart</forename><surname>Vekemans</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">X-ray Microspectroscopy and Imaging Group (XMI)</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<addrLine>Krijgslaan 281 S12</addrLine>
									<postCode>B-9000</postCode>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wim</forename><surname>Ceelen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Laboratory of Experimental Surgery</orgName>
								<orgName type="institution">Ghent University Hospital</orgName>
								<address>
									<postCode>B-9000</postCode>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Laszlo</forename><surname>Vincze</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">X-ray Microspectroscopy and Imaging Group (XMI)</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<addrLine>Krijgslaan 281 S12</addrLine>
									<postCode>B-9000</postCode>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">EUROPEAN SYNCHROTRON RADIATION FACILITY</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">271C68A572B152675044C9C50454D597</idno>
					<note type="submission">from: 29/10/2015 to: 02/11/2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-05-23T16:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">unknown</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=1, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>LS 2444</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Ovarian cancer, being one of the most common types of cancer in women worldwide, only has an overal cure rate of 30 %. 1,2 Intraperitoneal (IP) chemotherapy with cisplatin has been proven clinically to be an effective treatment for this type of cancer. 3 However, up-to-now little research has been performed on the optimization of IP protocols. Furthermore, it has been found the cancer cells develop resistance towards the drug relatively quickly, urging for more in-depth research on the tumor-drug interactions. 4  The nano-XRF measurements at ID16B were part of our attempts to unravel the resistance mechanism of cancer cells towards cisplatin, while a second goal was to assess the influence of temperature on the penetration depth of the cisplatin drug. At Ghent University Hospital, nude-foxn1nu female mice were injected with ovarian cancer cells in a matrigel matrix. These mice were treated with cisplatin IP (at two temperatures: 37°C and 41°C) two weeks after injection. The tumors were resected immediately after the IP treatment, fixed in paraformaldehyde and imbedded in parafin. Slices of 2 µm thickness were placed on ultralene® foil and analysed with the ID16B nano-probe. Optical microscopy images were used to correlate the structures found via XRF imaging with cell structures such as the cell membrane, the nucleus or the extracellular matrix.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Two types of XRF experiments have been performed on the tumor sections. Linescans covering the entire width of the samples were measured in order to obtain the penetration depth of the cisplatin drug in the tumor tissue (stepsize 100 nm). It could be shown thet IPC treatment at elevated temperatures leads to a higher penetration depth. The high sensitivity of the ID16B instrument was crucial in detecting the small Pt concentrations, which would have been undetectable using a laboratory setup. In view of our goal to optimize the IP protocol, the enhancing effect of elevated temperatures on the penetration depth of cisplatin drugs is of high relevance.. Secondly, high resolution maps (50 nm) of the tumor tissue were made. The XRF maps are used to study the elemental distribution of Pt and trace metals in the tumor tissue. In order to effectively kill the cancer cells, the drug must interact with its DNA in the cell nucleus. Hence, the submicron distribution of Pt revealed by the XRF images will be of huge importance when investigating its activity. The correlations between Pt and others metals are also of interest, because of possible synergetic effects. Figure-1 represents three XRF maps of P, Zn and Pt respectively. The P signal clearly reveals the outlines of the tumor cells, due to it being present in the pospholipid membranes of the cell structure. Zn is present in multiple cell structures and is notably concentrated in the nucleus. Comparing the P and Zn map with Pt, it is clear the regions with high Pt concentration are lying outside the tumor cells. Further investigations are needed in order to clarify the reason why Pt resides preferentially in the extracellular matrix (ECM) of the tumor tissue, hypothesises being a too short reaction time, high affinity the specific structures of the ECM or the resistance mechanism of the tumor cells preventing it from entering the cells. Information on the chemical structure of the Pt will be crucial when assessing this question. Furthermore, it was discovered Pt shows a strong correlation with Br and to a lesser extent with S. The Pt-S correlation might be due to interactions of the cisplatin drug with certain proteins present in the ECM. Br is a known trace element in human tissue, while its comparable chemical structure to Cl (both being halogens) could explain its affinity towards cisplatin, since Pt is complexed with Cl in this molecule. Once again, further research is needed to clarify the interactions Pt with these two elements. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure- 1</head><label>1</label><figDesc>Figure-1 XRF maps of P, Zn and Pt (50 nm step size, 0.1 s dwell time) concentration were determined using a Monte Carlo simulation aided quantification procedure</figDesc><graphic coords="2,34.20,405.00,422.95,133.65" type="bitmap" /></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</title>
		<author>
			<persName><forename type="first">Jacques</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hai‐rim</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Freddie</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Colin</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Donald</forename><forename type="middle">Maxwell</forename><surname>Parkin</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.25516</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cancer</title>
		<title level="j" type="abbrev">Intl Journal of Cancer</title>
		<idno type="ISSN">0020-7136</idno>
		<idno type="ISSNe">1097-0215</idno>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2893" to="2917" />
			<date type="published" when="2010-06-17">2010</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Ferlay, J.; Shin, H.-R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. International Journal of Cancer 2010, 127, 2893-2917.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The biology of ovarian cancer: new opportunities for translation</title>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">C</forename><surname>Bast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bryan</forename><surname>Hennessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gordon</forename><forename type="middle">B</forename><surname>Mills</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrc2644</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Cancer</title>
		<title level="j" type="abbrev">Nat Rev Cancer</title>
		<idno type="ISSN">1474-175X</idno>
		<idno type="ISSNe">1474-1768</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="415" to="428" />
			<date type="published" when="2009-06">2009</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Bast, R. C.; Hennessy, B.; Mills, G. B. Nat Rev Cancer 2009, 9, 415-428.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</title>
		<author>
			<persName><forename type="first">N</forename><surname>Van Der Vange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Van Goethem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Zoetmulder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kaag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Van De Vaart</surname></persName>
		</author>
		<author>
			<persName><surname>Ten Bokkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Huinink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Beijnen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="663" to="668" />
		</imprint>
	</monogr>
	<note type="raw_reference">van der Vange, N.; van Goethem, A. R.; Zoetmulder, F. A.; Kaag, M. M.; van de Vaart, P. J.; ten Bokkel Huinink, W. W.; Beijnen, J. H. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2000, 26, 663-668.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Siddik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Oncogene ; Laforce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carlier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vekemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Villanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tucoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ceelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vincze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">29999</biblScope>
			<date type="published" when="2003">2003. 2016</date>
		</imprint>
	</monogr>
	<note>The data gathered during this beamtime yielded information for two publications</note>
	<note type="raw_reference">Siddik, Z. H. Oncogene 2003, 22, 7265-7279. The data gathered during this beamtime yielded information for two publications: Laforce, B.; Carlier, C.; Vekemans, B.; Villanova, J.; Tucoulou, R.; Ceelen, W.; Vincze, L., Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging. Scientific Reports 2016, 6, 29999.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer</title>
		<author>
			<persName><forename type="first">Charlotte</forename><surname>Carlier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brecht</forename><surname>Laforce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Stijn</forename><forename type="middle">J M</forename><surname>Van Malderen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Félix</forename><surname>Gremonprez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Remi</forename><surname>Tucoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julie</forename><surname>Villanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Olivier</forename><surname>De Wever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Laszlo</forename><surname>Vincze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Frank</forename><surname>Vanhaecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wim</forename><surname>Ceelen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jpba.2016.09.004</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmaceutical and Biomedical Analysis</title>
		<title level="j" type="abbrev">Journal of Pharmaceutical and Biomedical Analysis</title>
		<idno type="ISSN">0731-7085</idno>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="256" to="262" />
			<date type="published" when="2016-11">2016</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Carlier, C.; Laforce, B.; Van Malderen, S. J. M.; Gremonprez, F.; Tucoulou, R.; Villanova, J.; De Wever, O.; Vincze, L.; Vanhaecke, F.; Ceelen, W., Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer. Journal of Pharmaceutical and Biomedical Analysis 2016, 131, 256-262.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
